Project Grant R21DE035749
- The National Institute of Dental and Craniofacial Research awarded the Stowers Institute For Medical Research $371,250 on March 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the pathogenesis, phenotypic variation, and prevention of craniofacial anomalies. The project examines how genetic and environmental factors interact to produce craniofacial birth defects—conditions such as cleft lip and palate, micrognathia, and craniosynostosis that account...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded $315,000 to the University of California, Los Angeles on July 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate bone morphogenetic protein (BMP)-dependent mechanisms underlying mandibular outgrowth and to resolve molecular pathways disrupted in micrognathia, a congenital anomaly affecting mandibular...
- The National Institute of Dental and Craniofacial Research awarded the University of Texas Health Science Center at Houston $400,000 on August 24, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121, assistance type: Project Grant R56DE036303). The recipient will investigate the function of TWIST1 and its regulatory pathway in craniofacial bone development, focusing on the genetic interaction between the epithelial-to-mesenchymal transition transcription factor TWIST1 and...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded $128,191 to the University of California Irvine on May 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121). The award supports a project grant (K99DE034828) to identify non-coding genetic sources of mammalian craniofacial variation and test their functional impact on facial morphogenesis. The research addresses the...
- The National Institute of Dental and Craniofacial Research awarded $528,460 to the University of Pennsylvania on July 2, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop single-scan multi-contrast cranial MRI technology for pediatric patients with congenital birth defects. The funded work addresses the clinical need to reduce ionizing radiation exposure in children evaluated for craniofacial skeletal pathologies such as craniosynostosis, a condition affecting...
- The National Institute of Dental and Craniofacial Research awarded the Stowers Institute for Medical Research $124,200 on September 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate ribosome biogenesis regulation of neural crest cell differentiation in development and disease. The funded research examines how ribosomal RNA transcription and ribosome biogenesis control neural crest cell fate acquisition and differentiation during craniofacial...
- The National Institute of Dental and Craniofacial Research awarded the University of New Mexico $305,000 under the Oral Diseases and Disorders Research program (CFDA 93.121) on June 5, 2026. The award funds research into the mechanisms by which PRDM3 and PRDM16 chromatin modifiers control craniofacial cartilage development. The research uses genetic mouse models, in vitro cell culture systems, and molecular tools to test whether precise levels of these paralogs fine-tune Wnt/β-catenin...
- The National Institute of Dental and Craniofacial Research awarded the Regents of the University of Michigan $710,519 on August 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to establish a comprehensive, web-based developmental monitoring system for infants and toddlers with orofacial clefts. The project will track developmental status and trajectories across multiple domains—social/communication/cognition skills, motor abilities, early relational health, sleep,...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Illinois $249,000 on August 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop bone-like organoids that elucidate how immune responses influence craniofacial bone healing and regeneration. The recipient will establish bone-like organoids as predictive tools for craniofacial bone repair...
- The National Institute of Dental and Craniofacial Research awarded The Jackson Laboratory $795,730 on March 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct systems genomics research on palate morphogenesis and facial shape variation in genetically diverse mice. The research leverages mouse models to elucidate the genetic, transcriptional, and histological mechanisms underlying craniofacial morphogenesis, with particular focus on understanding how...
The National Institute of Dental and Craniofacial Research awarded $495,467 to Seattle Children's Hospital on August 21, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop a visual communication tool addressing craniofacial microsomia patient education and clinician communication. Craniofacial microsomia is the third most common congenital craniofacial condition, affecting approximately 1 in 3,000 to 5,600 births and presenting with variable underdevelopment of facial structures, primarily the jaw and ear(s), with potential impacts on hearing, speech, respiration, and appearance. The project addresses a documented "linguistic problem of morphology"—the inherent difficulty in precisely describing complex anatomical variations using language alone—by creating semantically-augmented anatomical graphics to bridge clinical terminology and patient understanding. The recipient, Seattle Children's Research Institute (doing business as Seattle Children's Hospital), will execute a stakeholder-centered co-design approach across three phases: stakeholder-specific needs assessment through in-depth interviews with caregivers and clinicians; co-design workshops to create context scenarios and paper prototypes; and integrated prototype development and refinement through focus groups with combined stakeholders. The work is performed in Seattle, Washington, with a period of performance from August 21, 2026, through August 20, 2028. The assistance type is a Project Grant, which provides support for discrete, circumscribed research projects in the institute's priority areas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $495.5k | 8/24/26 |